Clinical trial
V501 Phase II Immunogenicity Study in Females Aged 9 to 17 Years
NCT00411749 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- V501 Phase II Immunogenicity Study in Females Aged 9 to 17 Years
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 11, 2006
- Completion date
- September 18, 2009
- Enrollment
- 107 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
hpv infections